Kan Li

机构：Sun Yat-sen University, Stomatology Hospital · ORCID：0000-0002-5762-7440

发表论文 98 篇 · 总被引 3921 次 · h-index 24

代表论文

• Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial (2024 · The Lancet · 被引 378)
• CEBPB dampens the cuproptosis sensitivity of colorectal cancer cells by facilitating the PI3K/AKT/mTOR signaling pathway (2024 · Saudi Journal of Gastroenterology · 被引 15)
• Suppression of the Prostaglandin I2–Type 1 Interferon Axis Induces Extramedullary Hematopoiesis to Promote Cardiac Repair After Myocardial Infarction (2025 · Circulation · 被引 13)
• Pembrolizumab plus chemotherapy with or without bevacizumab in East Asian participants with persistent, recurrent, or metastatic cervical cancer: results from KEYNOTE-826 final analysis (2025 · Journal of Gynecologic Oncology · 被引 8)
• Patient-reported outcomes from the phase 3, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/KEYNOTE-A18 study of pembrolizumab plus concurrent chemoradiotherapy in participants with high-risk locally advanced cervical cancer (2025 · Gynecologic Oncology · 被引 7)
• Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: A randomized, double-blind, phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study (2024 · Gynecologic Oncology · 被引 3)